Effects of the CYP 2D6 Genotype and Cigarette Smoking on the Steady‐State Plasma Concentrations of Fluvoxamine and Its Major Metabolite Fluvoxamino Acid in Japanese Depressed Patients

&NA; The effects of the cytochrome P450 (CYP) 2D6 genotype and cigarette smoking on the steady‐state plasma concentrations (Css) of fluvoxamine (FLV) and its demethylated metabolite fluvoxamino acid (FLA) were studied in 49 Japanese depressed patients receiving FLV 200 mg/d. The Css of FLV and FLA were measured by HPLC, and the wild‐type allele (*1) and two mutated alleles causing absent (*5) or decreased (*10) CYP 2D6 activity were identified by PCR methods. The patients were divided into three genotype groups by the number of mutated alleles: 12 cases with no (*1/*1), 27 cases with one (*1/*5 and *1/*10), and 10 cases with two (*5/*10 and *10/*10) mutated alleles. The means ± SD of the Css of FLV and FLA and the FLA/FLV ratio of all patients were 169.1 ± 147.5 ng/mL, 83.9 ± 52.7 ng/mL, and 0.71 ± 0.50, respectively. The Css of FLV and FLA were not significantly different among the three genotype groups. However, the FLA/FLV ratio was significantly lower in the patients with one (P < 0.05) and two (P < 0.01) mutated alleles than in those with no mutated allele. There was no significant difference between nonsmokers (n = 34) and smokers (n = 15) in these values. In the stepwise multiple regression, the Css of FLA (P < 0.05) and FLA/FLV ratio (P < 0.001) showed significant negative correlations with the number of mutated alleles, and the FLA/FLV ratio was significantly (P < 0.05) lower in women than in men. The present study suggests that the CYP 2D6 genotype and cigarette smoking have no major impact on the Css of FLV and FLA, though CYP 2D6 is involved in the demethylation of FLV.

[1]  L. Bertilsson,et al.  Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to theCYP2D6 genotype , 1996, Psychopharmacology.

[2]  G. Alfredsson,et al.  Concentrations of chlorpromazine and two of its active metabolites in plasma and cerebrospinal fluid of psychotic patients treated with fixed drug doses , 2004, Psychopharmacology.

[3]  N. Yasui-Furukori,et al.  Clinical implications of pharmacogenetics of antidepressants , 2002 .

[4]  L. Bertilsson,et al.  Low daily 10‐mg and 20‐mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19) , 2002, Clinical pharmacology and therapeutics.

[5]  O. Spigset,et al.  The major fluvoxamine metabolite in urine is formed by CYP2D6 , 2001, European Journal of Clinical Pharmacology.

[6]  L. Bertilsson,et al.  Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. , 2001, British journal of clinical pharmacology.

[7]  T. Someya,et al.  Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline. , 2000, Journal of clinical psychopharmacology.

[8]  F. Holsboer,et al.  Penetration of Amitriptyline, but Not of Fluoxetine, into Brain is Enhanced in Mice with Blood-Brain Barrier Deficiency Due to Mdr1a P-Glycoprotein Gene Disruption , 2000, Neuropsychopharmacology.

[9]  K. Otani,et al.  Pharmacogenetics of classical and new antipsychotic drugs. , 2000, Therapeutic drug monitoring.

[10]  C. Beasley,et al.  Olanzapine. Pharmacokinetic and pharmacodynamic profile. , 1999, Clinical pharmacokinetics.

[11]  T. Someya,et al.  Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients. , 1999, Therapeutic drug monitoring.

[12]  T. Kamataki,et al.  Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. , 1999, Journal of biochemistry.

[13]  K. Otani,et al.  Effects of the CYP2D6*10 allele on the steady‐state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia , 1999, Clinical pharmacology and therapeutics.

[14]  O. Spigset,et al.  Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance , 1999, European Journal of Clinical Pharmacology.

[15]  H. Wetzel,et al.  Nonlinear pharmacokinetics of fluvoxamine and gender differences. , 1998, Therapeutic drug monitoring.

[16]  O. Spigset,et al.  Non-linear fluvoxamine disposition. , 1998, British journal of clinical pharmacology.

[17]  L. Bertilsson,et al.  The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients. , 1997, Journal of clinical psychopharmacology.

[18]  K. Otani,et al.  Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. , 1997, Pharmacogenetics.

[19]  O. Spigset,et al.  Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms , 1997, European Journal of Clinical Pharmacology.

[20]  O. Wiborg,et al.  Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol. , 1996, Therapeutic drug monitoring.

[21]  C. Alm,et al.  Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity , 1996, Clinical pharmacology and therapeutics.

[22]  O. Wiborg,et al.  Steady‐state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism , 1996, Clinical pharmacology and therapeutics.

[23]  O. Spigset,et al.  A case of fluvoxamine intoxication demonstrating nonlinear elimination pharmacokinetics. , 1996, Journal of Clinical Psychopharmacology.

[24]  L. Bertilsson,et al.  Polymorphic Drug Oxidation , 1996 .

[25]  O. Spigset,et al.  Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans , 1995, Clinical pharmacology and therapeutics.

[26]  K. Otani,et al.  Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. , 1995, International clinical psychopharmacology.

[27]  O. Andreassen,et al.  Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. , 1995, Pharmacogenetics.

[28]  A. Chamberlain,et al.  Dose-dependent caffeine pharmacokinetics during severe sleep deprivation in humans. , 1995, International journal of clinical pharmacology and therapeutics.

[29]  M. Ingelman-Sundberg,et al.  Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. , 1994, Molecular pharmacology.

[30]  D. Schrenk,et al.  The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. , 1994, Pharmacogenetics.

[31]  G. Plosker,et al.  Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness. , 1993, Drugs.

[32]  J. Rabe-Jabłońska,et al.  [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders]. , 1993, Psychiatria polska.

[33]  K. Otani,et al.  Steady‐State Plasma Concentrations of Mianserin and Its Major Active Metabolite, Desmethylmianserin , 1993, Therapeutic drug monitoring.

[34]  M. Raghoebar,et al.  Single and Multiple Oral Dose Fluvoxamine Kinetics in Young and Elderly Subjects , 1992, Therapeutic drug monitoring.

[35]  H. Wetzel,et al.  Automated determination of fluvoxamine in plasma by column-switching high-performance liquid chromatography. , 1992, Clinical chemistry.

[36]  K. Otani,et al.  Steady‐state serum kinetics of zotepine , 1992 .

[37]  U. Meyer,et al.  Genetic polymorphism of debrisoquine oxidation: restriction fragment analysis and allele-specific amplification of mutant alleles of CYP2D6. , 1991, Methods in enzymology.

[38]  W. Fleischhacker,et al.  Influence of patient-related variables on clozapine plasma levels. , 1990, The American journal of psychiatry.

[39]  M. Jann,et al.  Effects of smoking on fluphenazine clearance in psychiatric inpatients , 1985, Biological Psychiatry.

[40]  J. Miners,et al.  Nonlinear Metabolic Disposition of Theophylline , 1984, Therapeutic drug monitoring.

[41]  V. Claassen.  Review of the animal pharmacology and pharmacokinetics of fluvoxamine. , 1983, British journal of clinical pharmacology.